scholarly journals EFFECTIVENESS OF LAUGHTER THERAPY VERSUS HUMOUR THERAPY ON BLOOD GLUCOSE LEVEL AMONG INDIVIDUALS DIAGNOSED WITH TYPE 2 DIABETES MELLITUS

2019 ◽  
Vol 10 (5) ◽  
pp. 67-71
Author(s):  
P Walter Jaisingh ◽  
S Vijayalakshmi ◽  
R Vijayaraghavan
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Blood Glucose Level ◽  
Glucose Level

scholarly journals PREVALENCE OF HYPOTHYROIDISM IN TYPE 2 DIABETES MELLITUS

2019 ◽  
Vol 3 (9) ◽  
Author(s):  
Dr. Harish Basera ◽  
Dr. K.C. Pant
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Blood Glucose Level ◽  
Glucose Level ◽  
Fasting Blood Glucose ◽  
Family History Of Diabetes ◽  
Increased Risk

Introduction: Thyroid hormone deficiency can lead to adverse health effects even death, if left untreated. It is a pathological condition known as hypothyroidism. Most common symptoms of hypothyroidism in adults are weight gain, fatigue, lethargy, cold intolerance, constipation, and dry skin. These clinical presentations can differ with age and sex, among other factors. Thyroid Stimulating Hormone (TSH), is associated with an increased risk of developing a number of clinical conditions, like cardiovascular diseases, diabetes, lung disease, malignant condition, and psychiatric disorders, both before and after the diagnosis of thyroid dysfunction. Type 2 Diabetes Mellitus (T2DM) is the chronic endocrine disease which is characterized by hyperglycemia resulting in impaired insulin secretion insulin resistance. Material and Methods: This prospective observational study was carried out at OPD of Dept. of Medicine at Govt. Doon Medical College and Hospital. The study period was between jan2019 to August 2019. The anthropometric measurements and demographic characteristics of patients included in the study were recorded. The clinical details and medications are entered into Excel sheet of Microsoft Excel 2013. Biochemical tests were done and reports were entered. Results: Prevalence of hypothyroidism in T2DM is found to be 10.94% in our study. Average BMI was observed to be 28.01 kg/m2 with SD of 3.39 kg/m2. Level of T3 and T4 were observed to be 0.98(0.23) ng/ml and 1.24(0.29) ng/ml respectively. Fasting blood glucose level was 133.05(17.81) mg/dl and post prandial blood glucose level was 201.54(27.33) mg/dl. Among all 112 patients, 71(63.39%) of cases had a family history of diabetes. Conclusion: It is noted that one-tenth of patients with type 2 diabetes mellitus has hypothyroidism. BMI was noted to be more than 28 kg/m2 among all patients. Hypothyroidism may be prevalent in T2DM patients due to duration of diabetes, obesity. To confirm the findings, more studies in this area are required. Keywords: T2DM, Hypothyroidism, TSH, T3, T4.

scholarly journals Clinical significance of the ADVANCE study for a practitioner: Possibility to treat and prevent complications of type 2 diabetes mellitus

2009 ◽  
Vol 55 (5) ◽  
pp. 6-9
Author(s):  
V N Shishkova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Blood Glucose Level ◽  
Glucose Level ◽  
Advance Study ◽  
Safe Control ◽  
Hypoglycemic Therapy

ADVANCE is a multicentre placebo-controlled randomized trial undertaken to investigate effects of intensive decrease of blood pressure and blood glucose level on the development of major micro- and macrovascular complications in patients with type 2 diabetes mellitus. Patients included in the study designed to evaluate results of intense glycemic control were given glyclazide modified release (diabeton MR) as the basic treatment. The main results of ADVANCE indicate that intense hypoglycemic therapy with the use of diabeton MR allows for efficient and safe control of blood glucose level with the reduction of the mean HbA1c level to 6.5% or less. Also, this treatment significantly decreases the risk of severe diabetic complications by 10% including nephropathy and proteinuria (by 21% and 30% respectively).

scholarly journals ID: 1014 Expanded autologous adipose derived stem cell transplantation for type 2 diabetes mellitus

2017 ◽  
Vol 4 (S) ◽  
pp. 88
Author(s):  
Phuong Thi-Bich Le ◽  
Phuc Van Pham ◽  
Ngoc Bich Vu ◽  
Loan Thi-Tung Dang ◽  
Ngoc Kim Phan
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Stem Cell ◽  
Blood Glucose ◽  
Blood Glucose Level ◽  
Glucose Level ◽  
Therapeutic Effects ◽  
Adipose Derived Stem Cell

Introduction: Type 2 diabetes mellitus (T2D) is the most common form of diabetes mellitus, accounting for 90% of diabetes mellitus in patients. At the present time, although T2D can be treated by various drugs and therapies using insulin replacement, reports have shown that complications including microvascular, macrovascular complications and therapy resistance can occur in patients on long term treatment. Stem cell therapy is regarded as a promising therapy for diabetes mellitus, including T2D. The aim of this study was to evaluate the safety and therapeutic effect of expanded autologous adipose derived stem cell (ADSC) transplantation for T2D treatment; the pilot study included 3 patients who were followed for 3 months. Methods: The ADSCs were isolated from stromal vascular fractions, harvested from the belly of the patient,and expanded for 21 days per previously published studies. Before transplantation, ADSCs were evaluated for endotoxin, mycoplasma contamination, and karyotype. All patients were transfused with ADSCs at 1-2x106 cells/kg of body weight.Patients were evaluated for criteria related to transplantation safety and therapeutic effects; these included fever, blood glucose level before transplantation of ADSCs, and blood glucose level after transplantation (at 1, 2 and 3 months). Results: The results showed that all samples of ADSCs exhibited the MSC phenotype with stable karyotype (2n=46), there was no contamination of mycoplasma, and endotoxin levels were low (<0.25 EU/mL). No adverse effects were detected after 3 months of transplantation. Decreases of blood glucose levels were recorded in all patients. Conclusion: The findings from this initial study show that expanded autologous ADSCs may be a promising treatment for T2D.

scholarly journals Expanded autologous adipose derived stem cell transplantation for type 2 diabetes mellitus

2016 ◽  
Vol 3 (12) ◽  
pp. 1034 ◽  
Author(s):  
Phuong Thi-Bich Le ◽  
Phuc Van Pham ◽  
Ngoc Bich Vu ◽  
Loan Thi-Tung Dang ◽  
Ngoc Kim Phan
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Stem Cell ◽  
Blood Glucose ◽  
Blood Glucose Level ◽  
Glucose Level ◽  
Therapeutic Effects ◽  
Adipose Derived Stem Cell

Introduction: Type 2 diabetes mellitus (T2D) is the most common form of diabetes mellitus, accounting for 90% of diabetes mellitus in patients. At the present time, althoughT2D can be treated by various drugs and therapies using insulin replacement, reports have shown that complications including microvascular, macrovascular complications and therapy resistance can occur in patients on long term treatment. Stem cell therapy is regarded as a promising therapy for diabetes mellitus, including T2D. The aim of this study was to evaluate the safety and therapeutic effect of expanded autologous adipose derived stem cell (ADSC) transplantation for T2D treatment; the pilot study included 3 patients who were followed for 3 months. Methods: The ADSCs were isolated from stromal vascular fractions, harvested from the belly of the patient,and expanded for 21 days per previously published studies. Before transplantation, ADSCs were evaluated for endotoxin, mycoplasma contamination, and karyotype.All patients were transfused with ADSCs at 1-2x106 cells/kg of body weight.Patients were evaluated for criteria related to transplantation safety and therapeutic effects; these included fever, blood glucose level before transplantation of ADSCs, and blood glucose level after transplantation (at 1, 2 and 3 months).Results: The results showed that all samples of ADSCs exhibited the MSC phenotype with stable karyotype (2n=46), there was no contamination of mycoplasma, and endotoxin levels were low (0.25 EU/mL). No adverse effects were detected after 3 months of transplantation. Decreases of blood glucose levels were recorded in all patients. Conclusion: The findings from this initial study show that expanded autologous ADSCs may be a promising treatment for T2D.

Sign in / Sign up

Export Citation Format

Share Document